Generated automatically from the NAFDAC register, WHO alerts and community data as of today. This is not medical advice. Always follow your doctor or pharmacist.
From the official U.S. FDA label for spironolactone, the active ingredient registered with NAFDAC.
Spironolactone tablets are an aldosterone antagonist indicated for: The treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hospitalization for heart failure ( 1.1 ). Use as an add-on therapy for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.2 ). …
The following clinically significant adverse reactions are described elsewhere in the labeling: Hyperkalemia [ see Warnings and Precautions (5.1) ] Hypotension and Worsening Renal Function [ see Warnings and Precautions (5.2) ] Electrolyte and Metabolic Abnormalities [ see Warnings and Precautions (5.3) ] Gynecomastia [ see Warnings and Precautions (5.4) ] Impaired neurological function/ coma in patients with hepatic impairment, cirrhosis and ascites [ see Use in Specific Populations (8.7) ] The following adverse reactions associated with the use of spironolactone were identified in clinical trials or postmarketing reports. …
Spironolactone tablets are contraindicated in the patients with: Hyperkalemia Addison’s disease Concomitant use of eplerenone Spironolactone Tablets are contraindicated in patients with ( 4 ): Hyperkalemia Addison’s disease Concomitant use of eplerenone
Hyperkalemia: Monitor serum potassium within one week of initiation and regularly thereafter (5.1). Hypotension and Worsening Renal Function: Monitor volume status and renal function periodically (5.2). Electrolyte and Metabolic Abnormalities: Monitor serum electrolytes, uric acid and blood glucose periodically (5.3). Gynecomastia: Spironolactone tablets can cause gynecomastia (5.4). 5.1 Hyperkalemia Spironolactone tablets can cause hyperkalemia. …
8.1 Pregnancy Risk Summary Based on mechanism of action and findings in animal studies, spironolactone may affect sex differentiation of the male during embryogenesis (see Data) . Rat embryofetal studies report feminization of male fetuses and endocrine dysfunction in females exposed to spironolactone in utero. …
Add the expiry date on your pack for a full Trust Score.
Alpadactone Tablets_ contains Spironolactone (50 mg), as tablet, according to its NAFDAC registration record.
Yes. Alpadactone Tablets_ is listed on the NAFDAC register under registration number A4-1472, and its registration is active as of 28 October 2026.
No WHO falsified or substandard medical product alert currently matches Alpadactone Tablets_ in our automatically synced alert list.
Run a free authenticity scan with the NAFDAC number A4-1472, your pack's expiry date and batch number to get a Trust Score, compare the pack with the NAFDAC record (ingredient, strength, form, manufacturer), and buy only from licensed pharmacies.
Spironolactone tablets are an aldosterone antagonist indicated for: The treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hospitalization for heart failure ( 1.1 ). Use as an add-on therapy for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal (Summarised from the official U.S. FDA label for spironolactone. Always follow your doctor or pharmacist.)
Reviews are personal experiences from PillVera users, not medical advice. Report side effects to your doctor and to NAFDAC.